-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$26.60243.23% Upside
Vir Biotechnology, Inc. Frequently Asked Questions
-
What analysts cover Vir Biotechnology, Inc.?
Vir Biotechnology, Inc. has been rated by research analysts at Barclays, Morgan Stanley, Goldman Sachs, Needham in the past 90 days.